Cabaletta Bio Reveals CABA-201's Positive Clinical Safety And Efficacy Data

(RTTNews) - Cabaletta Bio, Inc. (CABA), a clinical-stage biotechnology company focused on autoimmune diseases, announced Monday new and updated clinical data on CABA-201, presenting positive clinical safety and efficacy results.

In pre-market activity on the Nasdaq, the shares were gaining around 6.9 percent to trade at $3.2400.

The latest data showed the potential to achieve drug-free, compelling clinical responses based on eight patients dosed across the ongoing Phase 1/2 RESET-Myositis, RESET-SLE and RESET-SSc clinical trials.

Cabaletta noted that CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, was designed to deeply and transiently deplete CD19-positive B cells following a one-time infusion that may enable a reset of the immune system with the potential for durable remission without chronic immunosuppressive therapies in patients with autoimmune diseases.

Cabaletta is currently evaluating CABA-201 in the RESET clinical development program across five company-sponsored clinical trials that each have disease-specific cohorts with six patients per cohort. Treatment with CABA-201 in each clinical trial includes a preconditioning regimen of fludarabine and cyclophosphamide, consistent with the dosing regimen used in the third-party academic studies, except for the RESET-PV trial which is evaluating CABA-201 without preconditioning.

The company noted that the data from the trials were presented in oral and poster presentations at the American College of Rheumatology (ACR) Convergence 2024.

For More Such Health News, visit rttnews.com